Last reviewed · How we verify

Aclidinium Bromide 200 µg — Competitive Intelligence Brief

Aclidinium Bromide 200 µg (Aclidinium Bromide 200 µg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist (LAMA). Area: Respiratory / Pulmonology.

phase 3 Long-acting muscarinic antagonist (LAMA) Muscarinic M3 receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Aclidinium Bromide 200 µg (Aclidinium Bromide 200 µg) — AstraZeneca. Aclidinium bromide is a long-acting muscarinic antagonist that blocks M3 receptors in airway smooth muscle to prevent bronchoconstriction and improve airflow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aclidinium Bromide 200 µg TARGET Aclidinium Bromide 200 µg AstraZeneca phase 3 Long-acting muscarinic antagonist (LAMA) Muscarinic M3 receptor
Tiotropium/Formoterol Tiotropium/Formoterol Neutec Ar-Ge San ve Tic A.Ş marketed Long-acting anticholinergic/long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor (tiotropium); Beta-2 adrenergic receptor (formoterol)
Budesonide/formoterol and tiotropium Budesonide/formoterol and tiotropium Brian J Lipworth marketed Combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
tolterodine , mirabegron tolterodine , mirabegron Far Eastern Memorial Hospital marketed Antimuscarinic and beta-3 adrenergic agonist combination Muscarinic M3 receptor and beta-3 adrenergic receptor
Tiotropium & olodaterol Tiotropium & olodaterol University of Dundee marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; beta-2 adrenergic receptor
TIO/OLO TIO/OLO GlaxoSmithKline marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor and beta-2 adrenergic receptor
Trimbow pMDI Trimbow pMDI Medicines Evaluation Unit Ltd marketed Triple combination inhaler (ICS/LABA/LAMA) Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist (LAMA) class)

  1. GlaxoSmithKline · 9 drugs in this class
  2. AstraZeneca · 3 drugs in this class
  3. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
  4. Chiesi Farmaceutici S.p.A. · 1 drug in this class
  5. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
  6. Lupin, Inc. · 1 drug in this class
  7. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aclidinium Bromide 200 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/aclidinium-bromide-200-g. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: